Immunovant Inc (NASDAQ: IMVT) on Tuesday, plunged -9.07% from the previous trading day, before settling in for the closing price of $15.22. Within the past 52 weeks, IMVT’s price has moved between $12.72 and $34.47.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -49.30%. With a float of $68.32 million, this company’s outstanding shares have now reached $147.20 million.
The firm has a total of 207 workers. Let’s measure their productivity. In terms of profitability, gross margin is 90.4%, operating margin of -27013.67%, and the pretax margin is -25478.07%.
Immunovant Inc (IMVT) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Immunovant Inc is 59.78%, while institutional ownership is 49.29%. The most recent insider transaction that took place on Apr 23 ’25, was worth 28,471. In this transaction Chief Technology Officer of this company sold 1,925 shares at a rate of $14.79, taking the stock ownership to the 209,243 shares. Before that another transaction happened on Apr 23 ’25, when Company’s Chief Medical Officer sold 2,349 for $14.79, making the entire transaction worth $34,742. This insider now owns 225,370 shares in total.
Immunovant Inc (IMVT) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.73 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -49.30% per share during the next fiscal year.
Immunovant Inc (NASDAQ: IMVT) Trading Performance Indicators
Immunovant Inc (IMVT) is currently performing well based on its current performance indicators. A quick ratio of 6.04 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.62, a number that is poised to hit -0.71 in the next quarter and is forecasted to reach -2.99 in one year’s time.
Technical Analysis of Immunovant Inc (IMVT)
Analysing the last 5-days average volume posted by the [Immunovant Inc, IMVT], we can find that recorded value of 1.33 million was lower than the volume posted last year of 1.64 million. As of the previous 9 days, the stock’s Stochastic %D was 39.54%. Additionally, its Average True Range was 1.08.
During the past 100 days, Immunovant Inc’s (IMVT) raw stochastic average was set at 6.75%, which indicates a significant increase from 4.06% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.74% in the past 14 days, which was higher than the 63.38% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.12, while its 200-day Moving Average is $24.79. Now, the first resistance to watch is $14.96. This is followed by the second major resistance level at $16.07. The third major resistance level sits at $16.69. If the price goes on to break the first support level at $13.23, it is likely to go to the next support level at $12.61. Now, if the price goes above the second support level, the third support stands at $11.50.
Immunovant Inc (NASDAQ: IMVT) Key Stats
Market capitalization of the company is 2.35 billion based on 169,861K outstanding shares. Right now, sales total 0 K and income totals -259,340 K. The company made 0 K in profit during its latest quarter, and -111,120 K in sales during its previous quarter.
